CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-16 | Prasad Raju Chief Financial Officer | Grant or award · Restricted Stock Units | +15,000 | 15,000 | ||
| 2024-10-14 | KASINGER JAMES R. General Counsel and Secretary | Sale | −1,089 | $46.28 | $50K | 62,597 |
| 2024-10-14 | Kulkarni Samarth Chief Executive Officer | Sale | −4,293 | $46.28 | $199K | 226,540 |
| 2024-10-13 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | +2,113 | 63,686 | ||
| 2024-10-13 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Restricted Stock Units | −2,113 | 4,227 | ||
| 2024-10-13 | Kulkarni Samarth Chief Executive Officer | Option exercise | +8,333 | 230,833 | ||
| 2024-10-13 | Kulkarni Samarth Chief Executive Officer | Option exercise · Restricted Stock Units | −8,333 | 16,667 | ||
| 2024-08-08 | Kulkarni Samarth Chief Executive Officer | Gift | −100,000 | 222,500 | ||
| 2024-06-21 | Bruno Julianne Chief Operating Officer | Sale | −3,366 | $56.09 | $189K | 6,745 |
| 2024-06-20 | Bruno Julianne Chief Operating Officer | Option exercise | +7,000 | 10,111 | ||
| 2024-06-20 | Bruno Julianne Chief Operating Officer | Option exercise · Restricted Stock Units | −7,000 | 0 | ||
| 2024-05-30 | George Simeon Director | Grant or award · Stock Option (Right to buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Behbahani Ali Director | Grant or award · Stock Option (Right to buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Mahatme Sandesh Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2024-05-30 | High Katherine A Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Fardis Maria Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Greene John Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Treco Douglas A Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 | ||
| 2024-05-30 | Rommel Christian Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2024-05-30 | Fleming Harold Edward Director | Grant or award · Stock Option (Right to Buy) | +13,000 | 13,000 |
Page 12 of 46 · 910 trades